Emily Riehm Meier

List of Publications by Year
in descending order

107 papers	2,474 citations	279798 23 h-index	214800 47 g-index
111 all docs	111 docs citations	111 times ranked	2605 citing authors

#	Article	IF	Citations
1	Ring the Bell for Sickle Cell: Encouraging Advocacy in an Underserved Community. Health Promotion Practice, 2022, 23, 560-562.	1.6	0
2	A randomized, placebo-controlled, double-blind trial of canakinumab in children and young adults with sickle cell anemia. Blood, 2022, 139, 2642-2652.	1.4	17
3	Optimizing transfusion therapy for survivors of Haemoglobin Bart's hydrops fetalis syndrome: Defining the targets for <scp>haemoglobinâ€H</scp> fraction and â€œfunctionalâ€•haemoglobin level. British Journal of Haematology, 2022, 197, 373-376.	2.5	4
4	No child left behind: Building a comprehensive sickle cell disease care oasis in the Lake County, Indiana care desert. Pediatric Blood and Cancer, 2022, , e29619.	1.5	1
5	In Remembrance: Dr. Kwaku Ohene-Frempong. , 2022, 19, .		0
6	Outcomes of haemoglobin Bartâ€™s hydrops fetalis following intrauterine transfusion in Ontario, Canada. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2021, 106, 51-56.	2.8	9
7	What are the key considerations when prescribing pharmacotherapy for sickle cell anemia?. Expert Opinion on Pharmacotherapy, 2021, 22, 5-8.	1.8	0
8	Erythrocyte disorders. , 2021, , 529-560.		0
9	Hematopoietic stem cell transplant referral patterns for children with sickle cell disease vary among pediatric hematologist/oncologistsâ€™ practice focus: A Sickle Cell Transplant Advocacy and Research Alliance (STAR) study. Pediatric Blood and Cancer, 2021, 68, e28861.	1.5	9
10	Implementing newborn screening for sickle cell disease in Korle Bu Teaching Hospital, Accra: Results and lessons learned. Pediatric Blood and Cancer, 2021, 68, e29068.	1.5	12
11	Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial. JMIR Research Protocols, 2021, 10, e27650.	1.0	8
12	How we coordinate care for uninsured children with nonmalignant hematologic disorders. Pediatric Blood and Cancer, 2021, 68, e29103.	1.5	0
13	Investigating Role of Ferritin in Ex Vivo Erythropoiesis by Block-face SEM and STEM-EELS. Microscopy and Microanalysis, 2021, 27, 510-512.	0.4	0
14	Importance of sickle cell trait counseling for adolescents and young adults. Pediatric Blood and Cancer, 2021, 68, e29300.	1.5	0
15	Use of dual-electron probes reveals the role of ferritin as an iron depot in exÂvivo erythropoiesis. IScience, 2021, 24, 102901.	4.1	1
16	Initial Safety and Efficacy Results from the Phase II, Multicenter, Open-Label Solace-Kids Trial of Crizanlizumab in Adolescents with Sickle Cell Disease (SCD). Blood, 2021, 138, 12-12.	1.4	5
17	Multispectral Imaging for Microchip Electrophoresis Enables Point-of-Care Newborn Hemoglobin Variant Screening. Blood, 2021, 138, 2956-2956.	1.4	0
18	Alvin Zipursky (1930â€“2021): an unsurpassable mentor, counselor, and child health advocate. Pediatric Research, 2021, , .	2.3	0

#	Article	IF	Citations
19	Adherence to Quality of Care Indicators and Location of Sickle Cell Care Within Indiana. Journal of Community Health, 2020, 45, 81-87.	3.8	10
20	Not all red cells sickle the same: Contributions of the reticulocyte to disease pathology in sickle cell anemia. Blood Reviews, 2020, 40, 100637.	5.7	21
21	Sickle cell disease in Germany: Early insights from a national registry. Pediatric Blood and Cancer, 2020, 67, e28168.	1.5	2
22	Sickle cell disease: Progress made & challenges ahead. Indian Journal of Medical Research, 2020, 151, 505.	1.0	9
23	Addressing Recruitment Challenges in the Engage-HU Trial in Young Children with Sickle Cell Disease. Blood, 2020, 136, 26-27.	1.4	0
24	Study Design and Initial Baseline Characteristics in Solace-Kids: Crizanlizumab in Pediatric Patients with Sickle Cell Disease. Blood, 2020, 136, 22-24.	1.4	0
25	Hydroxycarbamide treatment in children with Sickle Cell Anaemia is associated with more intact white matter integrity: a quantitative MRI study. British Journal of Haematology, 2019, 187, 238-245.	2.5	11
26	Impact of a transition program with navigator on loss to followâ€up, medication adherence, and appointment attendance in hemoglobinopathies. Pediatric Blood and Cancer, 2019, 66, e27781.	1.5	33
27	Sickle cell disease: Reducing the global disease burden. International Journal of Laboratory Hematology, 2019, 41, 82-88.	1.3	61
28	Newborn Screening With Sickle Cell Point of Care: A Valuable Resource in Low-Income Settings. Pediatrics, 2019, 144, e20191681.	2.1	2
29	End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings. Blood Advances, 2019, 3, 4002-4020.	5.2	21
30	Characterization of natural killer cells expressing markers associated with maturity and cytotoxicity in children and young adults with sickle cell disease. Pediatric Blood and Cancer, 2019, 66, e27601.	1.5	5
31	Pointâ€ofâ€care screening for sickle cell disease in lowâ€resource settings: A multiâ€center evaluation of HemoTypeSC, a novel rapid test. American Journal of Hematology, 2019, 94, 39-45.	4.1	56
32	Double-Blind, Randomized Study of Canakinumab Treatment in Pediatric and Young Adult Patients with Sickle Cell Anemia. Blood, 2019, 134, 615-615.	1.4	3
33	A Novel Sickle Cell Outreach Program Improves Access to TCD Screening, Vaccines and Hydroxyurea in a Medically Underserved Area. Blood, 2019, 134, 4696-4696.	1.4	1
34	Pediatric Hematologist/Oncologists' Beliefs about Hematopoietic Stem Cell Transplant for Children with Sickle Cell Disease: A Sickle Cell Transplant Advocacy and Research Alliance (STAR) Study. Blood, 2019, 134, 2164-2164.	1.4	0
35	Clinical Practice Patterns for Hydroxyurea Initiation in Young Children with Sickle Cell Disease. Blood, 2019, 134, 4713-4713.	1.4	0
36	Diverse manifestations of acute sickle cell hepatopathy in pediatric patients with sickle cell disease: A case series. Pediatric Blood and Cancer, 2018, 65, e27060.	1.5	12

#	Article	IF	Citations
37	Access to hematopoietic stem cell transplant for patients with sickle cell anemia. Pediatric Blood and Cancer, 2018, 65, e27105.	1.5	5
38	Rhesus disease: a global prevention strategy. The Lancet Child and Adolescent Health, 2018, 2, 536-542.	5.6	15
39	Red blood cell specifications for patients with hemoglobinopathies: a systematic review and guideline. Transfusion, 2018, 58, 1555-1566.	1.6	55
40	Early initiation of inhaled corticosteroids does not decrease acute chest syndrome morbidity in pediatric patients with sickle cell disease. Blood Cells, Molecules, and Diseases, 2018, 71, 55-62.	1.4	10
41	Iron overload in transfusion-dependent survivors of hemoglobin Bartâ€™s hydrops fetalis. Haematologica, 2018, 103, e184-e187.	3.5	8
42	Treatment Options for Sickle Cell Disease. Pediatric Clinics of North America, 2018, 65, 427-443.	1.8	39
43	Inspiring AWE. , 2018, , .		6
44	Clinical features of children, adolescents, and adults with coexisting hypermobility syndromes and von Willebrand disease. Pediatric Blood and Cancer, 2018, 65, e27370.	1.5	6
45	Exploring the Needs of Adolescents With Sickle Cell Disease to Inform a Digital Self-Management and Transitional Care Program: Qualitative Study. JMIR Pediatrics and Parenting, 2018, 1, e11058.	1.6	19
46	Risk-Based Therapies for Sickle Cell Disease. , 2018, , 87-110.		0
47	Increasing Incidence and Prevalence of Pathologic Hemoglobinopathies Among Children in Ontario, Canada from 1991-2013. Blood, 2018, 132, 4698-4698.	1.4	3
48	Effect of Hydroxyurea Therapy on Pulmonary Function in Children with Sickle Cell Anemia. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 689-691.	5.6	21
49	A systematic review of the literature for severity predictors in children with sickle cell anemia. Blood Cells, Molecules, and Diseases, 2017, 65, 86-94.	1.4	27
50	The severity of anaemia depletes cerebrovascular dilatory reserve in children with sickle cell disease: a quantitative magnetic resonance imaging study. British Journal of Haematology, 2017, 176, 280-287.	2.5	60
51	Managing sickle cell carrier results generated through newborn screening in Ontario: a precedent-setting policy story. Genetics in Medicine, 2017, 19, 625-627.	2.4	5
52	Homozygous Î±â€thalassemia: Challenges surrounding early identification, treatment, and cure. Pediatric Blood and Cancer, 2017, 64, 151-155.	1.5	7
53	Pediatric sickle cell disease: past successes and future challenges. Pediatric Research, 2017, 81, 249-258.	2.3	16
54	Cranial epidural hematomas: A case series and literature review of this rare complication associated with sickle cell disease. Pediatric Blood and Cancer, 2017, 64, e26237.	1.5	11

#	Article	IF	Citations
55	Hydroxyurea for SCA in Africa: no malaria harm. Blood, 2017, 130, 2575-2576.	1.4	0
56	Association of wheeze with lung function decline in children with sickle cell disease. European Respiratory Journal, 2017, 50, 1602433.	6.7	1
57	Examination of Reticulocytosis among Chronically Transfused Children with Sickle Cell Anemia. PLoS ONE, 2016, 11, e0153244.	2.5	7
58	Provider Perspective on Integrative Medicine for Pediatric Sickle Cell Disease-related Pain. Global Advances in Health and Medicine, 2016, 5, 44-50.	1.6	8
59	Hydroxyurea Therapy for Children With Sickle Cell Anemia in Subâ€Saharan Africa: Rationale and Design of the REACH Trial. Pediatric Blood and Cancer, 2016, 63, 98-104.	1.5	41
60	Emerging point-of-care technologies for sickle cell disease screening and monitoring. Expert Review of Medical Devices, 2016, 13, 1073-1093.	2.8	49
61	Effectiveness of red blood cell exchange, partial manual exchange, and simple transfusion concurrently with iron chelation therapy in reducing iron overload in chronically transfused sickle cell anemia patients. Transfusion, 2016, 56, 1707-1715.	1.6	38
62	Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemiaâ€"TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet, The, 2016, 387, 661-670.	13.7	375
63	Early Reticulocytosis and Anemia Are Associated with Abnormal and Conditional Transcranial Doppler Velocities in Children withÂSickleÂCellÂAnemia. Journal of Pediatrics, 2016, 169, 227-231.e1.	1.8	19
64	Agreement Between R2 and R2* Liver Iron Estimates Is Independent of the Type of Iron Removal Therapy: Results from the Twitch Trial. Blood, 2016, 128, 1274-1274.	1.4	3
65	Initial Results of a Randomized Controlled Trial of Computerized Working Memory Training in Pediatric Sickle Cell Disease. Blood, 2016, 128, 247-247.	1.4	1
66	Biomarkers of Disease Severity Predict Neurocognitive Functioning in Pediatric SCD. Blood, 2016, 128, 248-248.	1.4	1
67	Evaluation of a Novel Newborn Screening Follow-up Program for Infants with Sickle Cell Disease. Blood, 2016, 128, 2344-2344.	1.4	0
68	Healthâ€related quality of life in children with sickle cell anemia: Impact of blood transfusion therapy. American Journal of Hematology, 2015, 90, 139-143.	4.1	57
69	Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology, 2015, 90, 806-810.	4.1	21
70	Hb S/Â+-thalassemia due to Hb sickle and a novel deletion of DNase I hypersensitive sites HS3 and HS4 of the Â locus control region. Haematologica, 2015, 100, e166-e168.	3.5	6
71	Kaposiform lymphangiomatosis: Unifying features of a heterogeneous disorder. Pediatric Blood and Cancer, 2015, 62, 901-904.	1.5	44
72	Current attitudes of parents and patients toward hematopoietic stem cell transplantation for sickle cell anemia. Pediatric Blood and Cancer, 2015, 62, 1277-1284.	1.5	40

#	Article	IF	Citations
73	Absolute Reticulocyte Count Acts as a Surrogate for Fetal Hemoglobin in Infants and Children with Sickle Cell Anemia. PLoS ONE, 2015, 10, e0136672.	2.5	4
74	Higher Nocturnal and Awake Oxygen Saturations in Children with Sickle Cell Disease Receiving Hydroxyurea Therapy. Annals of the American Thoracic Society, 2015, 12, 1044-1049.	3.2	26
75	Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease. British Journal of Haematology, 2015, 168, 291-300.	2.5	192
76	Review of moyamoya disease and syndrome with special consideration of associations with sickle cell disease. Journal of Pediatric Neuroradiology, 2015, 03, 021-028.	0.1	0
77	TCD with Transfusions Changing to Hydroxyurea (TWiTCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell Anemia. Blood, 2015, 126, 3-3.	1.4	19
78	Early Pathogenesis of Sickle Cell Anemia: Absolute Reticulocyte Counts Are Correlated with Increased Detection of CD36+ Reticulocytes during the First Two Years of Postnatal Life. Blood, 2015, 126, 2181-2181.	1.4	0
79	Early Initiation of Inhaled Corticosteroids Does Not Decrease Acute Chest Syndrome Morbidity in Pediatric Patients with Sickle Cell Disease. Blood, 2015, 126, 988-988.	1.4	0
80	Perspective: We need a global solution. Nature, 2014, 515, S10-S10.	27.8	27
81	Reticulocytosis and anemia are associated with an increased risk of death and stroke in the newborn cohort of the <scp>Cooperative</scp><scp>Study</scp> of <scp>Sickle</scp><scp>Cell</scp><scp>Disease</scp>. American Journal of Hematology, 2014, 89, 904-906.	4.1	48
82	Improving Outcomes in Children with Sickle Cell Disease: Treatment Considerations and Strategies. Paediatric Drugs, 2014, 16, 255-266.	3.1	14
83	Current Attitudes of Parents and Patients towards Hematopoietic Stem Cell Transplantation for Sickle Cell Anemia. Biology of Blood and Marrow Transplantation, 2013, 19, S160-S161.	2.0	1
84	Factors Impacting Family Decisions to Pursue Transplantation for Children with Sickle Cell Disease. Biology of Blood and Marrow Transplantation, 2013, 19, S219-S220.	2.0	0
85	An educational symposium for patients with sickle cell disease and their families: Results from surveys of knowledge and factors influencing decisions about hematopoietic stem cell transplant. Pediatric Blood and Cancer, 2013, 60, 1946-1951.	1.5	17
86	Increased Reticulocytosis during Infancy Is Associated with Increased Hospitalizations in Sickle Cell Anemia Patients during the First Three Years of Life. PLoS ONE, 2013, 8, e70794.	2.5	19
87	Increased Pre-Transfusion Reticulocytosis Among Chronically Transfused Sickle Cell Disease Patients Is Associated With More Severe Cerebral Vasculopathy. Blood, 2013, 122, 1163-1163.	1.4	0
88	LIN28A-Mediated Expression Of Fetal Hemoglobin Ameliorates Erythrocyte Sickling. Blood, 2013, 122, 313-313.	1.4	3
89	Sickle Cell Disease in Children. Drugs, 2012, 72, 1.	10.9	39
90	A global perspective on sickle cell disease. Pediatric Blood and Cancer, 2012, 59, 386-390.	1.5	131

#	Article	IF	Citations
91	Risk Stratification in Pediatric Sickle Cell Disease Using Absolute Reticulocyte Counts. Blood, 2012, 120, 1014-1014.	1.4	0
92	Outcome and Clinical Characteristics of Clonal and Malignant Myeloid Transformation in Inherited Bone Marrow Failure Syndromes. Blood, 2012, 120, 1266-1266.	1.4	0
93	Sickle Cell Disease in Africa. American Journal of Preventive Medicine, 2011, 41, S398-S405.	3.0	470
94	Expression patterns of fetal hemoglobin in sickle cell erythrocytes are both patientâ€•and treatmentâ€specific during childhood. Pediatric Blood and Cancer, 2011, 56, 103-109.	1.5	12
95	Dosed Deficiency of Iron Restricts Terminal Maturation and Enucleation of Cultured Human Erythroblasts. Blood, 2011, 118, 1041-1041.	1.4	4
96	Ineffective Erythropoiesis and Production of Normoblasts with a Beta Thalassemia Major Phenotype Using CD34+ Cells From Healthy Donors. Blood, 2011, 118, 1085-1085.	1.4	0
97	POST Marketing Observational Study of Children (6 years or older) Treated with Deferasirox (Exjade) Tj ETQq1 1 0.784314 rgBT /Over	1.4	0
98	RH genotyping in a sickle cell disease patient contributing to hematopoietic stem cell transplantation donor selection and management. Blood, 2010, 116, 2836-2838.	1.4	45
99	Chelation Choices and Iron Burden Among Patients with Thalassemia in the 21st Century: a Report From the Thalassemia Clinical Research Network (TCRN) Longitudinal Cohort.. Blood, 2009, 114, 4056-4056.	1.4	5
100	Ineffective Erythropoiesis Caused by Phenylhydrazine Activates the Expression of GDF15 in Maturing Erythroblasts.. Blood, 2009, 114, 4032-4032.	1.4	0
101	The Impact of the Child with Thalassemia On the Family: Parental Assessment by Child Health Questionnaire.. Blood, 2009, 114, 1371-1371.	1.4	1
102	Combining Fetal Hemoglobin and Reticulocytosis to Index Clinical Severity of Sickle Cell Disease in Children.. Blood, 2009, 114, 2556-2556.	1.4	0
103	White Matter Integrity and Core Cognitive Function in Children Diagnosed with Sickle Cell Disease.. Blood, 2009, 114, 2589-2589.	1.4	0
104	Iron Depleted Erythropoiesis: Slow but Effective. Blood, 2008, 112, 418-418.	1.4	3
105	Gamma-Globin Gene Expression in Adult Human Erythroblasts Is Associated with Concurrent Changes in the Nuclear Protein Levels of at Least Seven Transcription Factors.. Blood, 2008, 112, 1866-1866.	1.4	0
106	The Emerging Role of RH Genotyping in Chronically Transfused Sickle Cell Disease Patients. Blood, 2008, 112, 3035-3035.	1.4	0
107	Use of Dual Electron Probes Reveals Role of Ferritin in Ex Vivo Erythropoiesis. SSRN Electronic Journal, 0, , .	0.4	0